Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery

Charles N. Landen, Arturo Chavez-Reyes, Corazon Bucana, Rosemarie Schmandt, Michael T. Deavers, Gabriel Lopez-Berestein, Anil K. Sood

Research output: Contribution to journalArticlepeer-review

625 Scopus citations


Inducing destruction of specific mRNA using small interfering RNA (siRNA) is a powerful tool in analysis of protein function, but its use as a therapeutic modality has been limited by inefficient or impractical delivery systems. We have used siRNA incorporated into the neutral liposome 1,2-dioleoyl-sn-glycero- 3-phosphatidylcholine (DOPC) for efficient in vivo siRNA delivery. In nude mice bearing i.p. ovarian tumors, nonsilencing siRNA tagged with the fluorochrome Alexa 555 was encapsulated into DOPC liposomes and shown to be taken up by the tumor as well as many major organs. Furthermore, DOPC-encapsulated siRNA targeting the onco-protein EphA2 was highly effective in reducing in vivo EphA2 expression 48 hours after a single dose as measured by both Western blot and immunohistochemistry. Therapy experiments in an orthotopic mouse model of ovarian cancer were initiated 1 week after injection of either HeyA8 or SKOV3ip1 cell lines. Three weeks of treatment with EphA2-targeting siRNA-DOPC (150 μg/kg twice weekly) reduced tumor growth when compared with a nonsilencing siRNA (SKOV3ip1: 0.35 versus 0.70 g; P = 0.020; HeyA8: 0.98 versus 1.51 g; P = 0.16). When EphA2-targeting siRNA-DOPC was combined with paclitaxel, tumor growth was dramatically reduced compared with treatment with paclitaxel and a nonsilencing siRNA (SKOV3ip1: 0.04 versus 0.22 g; P < 0.001; HeyA8: 0.21 versus 0.84 g; P = 0.0027). These studies show the feasibility of siRNA as a clinically applicable therapeutic modality.

Original languageEnglish (US)
Pages (from-to)6910-6918
Number of pages9
JournalCancer research
Issue number15
StatePublished - Aug 1 2005

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery'. Together they form a unique fingerprint.

Cite this